HIV Diagnostic Care for Every Life
Visit Abbott at the 22ND International AIDS Conference in Amsterdam
We are proud and excited to once again join over 20,000 global leaders, policy makers, researchers, and advocates in Amsterdam on 23-27 July 2018.
For over 15 years we have been the HIV diagnostic partner of choice for clinicians, ministries of health, global funders, NGOs, healthcare workers, and implementing partners all over the world. Over the years our products and services have assisted in the screening, monitoring, and care of millions of people living with HIV and associated co-morbidities.
Today we are the world’s leading global partner for HIV diagnostics tests, connectivity, data management, and field support. Over 120 countries use our tests to identify infections earlier, prevent onward transmissions, and change the trajectory of the AIDS epidemic.
Connect with us at AIDS 2018 to discover our new product innovation in HIV viral load, join our symposium on 24 July, and explore our HIV Diagnostic Care portfolio.
Join us at the Symposium
The Final Frontier: True ‘Point of Care’ Viral Load.
Chair: Luis MF Gonzalez MD, PhD. Director of Scientific Affairs, Abbott
Professor Amilcar Tanuri MD, PhD.
Molecular Virology, Molecular Genetic Dept, Federal University of Rio de Janeiro, Brazil.
Title: “m-PIMA, a PoC Platform Suitable for Monitoring VL in HIV Patients at any Level of the Health System”
Professor Matilu Mwau, Kenya
Director, Centre for Infectious and Parasitic Diseases Control Research (CIPDR), Kemri, Kenya
Title: “Viral Load Testing at the Point of Care”
Wilson Nyegenye, Uganda
National Laboratory Equipment and Logistics Coordinator, Ministry of Health-Central Public Health Laboratories
Title: “Public Private Partnership Benefits Towards Strengthening Health Service Delivery”
Much has been achieved to reach the ambitious UNAIDS goals of 90-90-90. Viral load monitoring is the cornerstone of the last 90 and is critical to ensure individual treatment response, effective use of costly second- and third-line antiretroviral medications, and minimal development and spread of resistance. However, countries face numerous challenges in scaling up HIV VL testing.
Abbott introduces the m-PIMA™ HIV-1/2 VL, a new POC viral load monitoring test on the m-PIMA™ platform designed to deliver a viral load result in less than 70 minutes to help overcome some of those challenges.
In this symposium leading global HIV experts provide practical information about their experience implementing the new technology in clinical settings and the impact on their clinical decision making when a VL result can be delivered at the point of care. Additionally the symposium offers an implementing country’s experience on the use of connectivity to facilitate full integration into healthcare networks.
Abbott HIV Diagnostics
At each key lifecycle stage Abbott stands side by side with health organizations, healthcare professionals and, those directly affected by HIV/AIDS. Our unique diagnostic capabilities, connectivity, and management solutions deliver actionable results that impact the lives of millions of people globally.
HIV Viral Load
m-PIMA™ HIV-1/2 VL
Find us at the 22nd International Conference
23rd – 27th July 2018
Visit us at Booth #411
Introducing a Breakthrough Point-of-Care Test, the m-PIMA™ HIV-1/2 VL
Abbott is proud to introduce the m-PIMA™ HIV-1/2 VL, a viral load monitoring tool, designed to provide healthcare professionals, especially in remote and underserved communities, with a fast, accurate and easy-to-use device to manage HIV in less than 70 minutes at the point of care.
Come see it at our Booth #411